- Global Pharma News & Resources

Availability of Preparatory Documents for the Combined General Meeting of May 27, 2020

Strasbourg, France, April 3, 2020, 5:45 p.m. CET - Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies, announced that the documentation related to the Combined General Meeting (ordinary and extraordinary sessions) of Transgene’s shareholders is available.


The notice of meeting, comprising the agenda and the draft resolutions was published in the Bulletin des Annonces Légales Obligatoires (BALO) n° 41 of April 3, 2020.


These notices include information on how to attend and vote at the General Meeting.



As a result of restrictions placed on the movement and gatherings of persons, the Company’s annual meeting of shareholders called for May 27, 2020 at 10 a.m. will exceptionally be held behind closed doors without the physical presence of its shareholders.

Shareholders are strongly encouraged to vote by mail in advance of the shareholder meeting or to appoint the Chairman of the meeting as your proxy.  On account of the possible effect of the Covid-19 pandemic on postal delivery times, it is recommended to return your voting forms as soon as practicable.  Because the meeting will be held without the presence of the shareholders, it will be possible to ask questions during the meeting.


The procedures and rules relative to the holding of this shareholder meeting, as well as the exercise of the right to request documents and submit written questions, are set out in the notice of meeting published on 3 April 2020 and are also posted at

Editor Details

  • Company:
    • Transgene
  • Name:
    • Transgene
Last Updated: 03-Apr-2020